Revised chronic kidney disease guideline published
Updated recommendations on how to manage chronic kidney disease are now available for healthcare professionals to access.
Entitled ‘KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease’ (CKD), the revised report has been created by the KDIGO Work Group.
As in the previous guideline, the Work Group used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of recommendations and expert judgment to develop consensus practice points.
New evidence led to the updating of recommendations in the chapters ‘Comprehensive Care in Patients with Diabetes and CKD and ‘Glucose-Lowering Therapies in Patients with Type 2 Diabetes and CKD’.
According to the authors, latest evidence did not change recommendations in the chapters ‘Glycemic Monitoring and Targets in Patients with Diabetes and CKD’, ‘Lifestyle interventions in Patients with Diabetes and CKD’, and ‘Approached to Management of Patients with Diabetes and CKD’.
The updated guideline includes 13 recommendations and 52 practice points for clinicians caring for people with diabetes and chronic kidney disease (CKD).
A focus on preserving kidney function and maintaining well-being is recommended using a layered approach to care, starting with a foundation of lifestyle interventions, self-management, and first-line pharmacotherapy (such as sodium–glucose cotransporter-2 inhibitors) demonstrated to improve clinical outcomes.
To this are added additional drugs with heart and kidney protection, such as glucagon-like peptide-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists, and interventions to control risk factors for CKD progression and cardiovascular events, such as blood pressure, glycemia, and lipids.
To read the new guideline, click here.